OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-12.26%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$277M
AUM Growth
+$277M
(-16%)
Cap. Flow
+$6.82M
Cap. Flow
% of AUM
2.47%
Top 10 Holdings %
Top 10 Hldgs %
42.56%
Holding
60
New
17
Increased
8
Reduced
14
Closed
11
Top Buys
| 1 |
Stereotaxis
STXS
|
$14.3M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$10.8M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$8.04M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$4.79M |
| 5 |
Quanterix
QTRX
|
$4.06M |
Top Sells
| 1 |
Lexicon Pharmaceuticals
LXRX
|
$9.31M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$6.35M |
| 3 |
Ironwood Pharmaceuticals
IRWD
|
$5.75M |
| 4 |
Arvinas
ARVN
|
$4.84M |
| 5 |
Viking Therapeutics
VKTX
|
$3.32M |
Sector Composition
| 1 | Healthcare | 97.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Codexis
CDXS
$246M
| $18.5M | 6.7% | 1,350,000 | – | – |
|
|
2
Stereotaxis
STXS
$261M
| $14.3M | 5.17% | +4,070,000 | New | +$14.3M |
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $14.1M | 5.09% | 1,365,000 | – | – |
|
4
Harrow
HROW
$1.44B
| $13.3M | 4.82% | 2,370,000 +160,000 | +7% | +$899K |
|
|
EIDX
5
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $11M | 3.97% | 305,550 | – | – |
|
|
TPTX
6
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $10.8M | 3.91% | +287,500 | New | +$10.8M |
|
|
AMRN
7
Amarin Corp
AMRN
$311M
| $9.78M | 3.54% | 645,000 | – | – |
|
|
ODT
8
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $9.11M | 3.29% | 350,000 -75,000 | -18% | -$1.95M |
|
9
Ocular Therapeutix
OCUL
$2.12B
| $8.44M | 3.05% | 2,775,000 -175,000 | -6% | -$532K |
|
10
Axogen
AXGN
$743M
| $8.38M | 3.03% | 700,000 -200,000 | -22% | -$2.39M |
|
11
uniQure
QURE
$896M
| $8.07M | 2.92% | 205,000 | – | – |
|
|
TVRD
12
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $8.04M | 2.91% | +440,000 | New | +$8.04M |
|
|
BOLD
13
DELISTED
Audentes Therapeutics, Inc
BOLD
| $8.01M | 2.9% | 285,000 +5,000 | +2% | +$140K |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $7.81M | 2.82% | 230,000 -80,000 | -26% | -$2.72M |
|
|
BPMC
15
DELISTED
Blueprint Medicines
BPMC
| $7.71M | 2.79% | 105,000 -20,000 | -16% | -$1.47M |
|
16
Cytokinetics
CYTK
$4.23B
| $7.4M | 2.67% | 650,000 -250,000 | -28% | -$2.85M |
|
17
Xoma
XOMA
$392M
| $7.39M | 2.67% | 375,000 -25,000 | -6% | -$493K |
|
18
Eton Pharmaceutcials
ETON
$464M
| $7.36M | 2.66% | 1,165,000 +90,000 | +8% | +$569K |
|
19
Acadia Pharmaceuticals
ACAD
$4.38B
| $7.2M | 2.6% | 200,000 | – | – |
|
20
Avalo Therapeutics
AVTX
$122M
| $7.19M | 2.6% | 2,185,536 | – | – |
|
|
BHVN
21
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $6.68M | 2.41% | 160,000 +10,000 | +7% | +$417K |
|
22
PTC Therapeutics
PTCT
$3.92B
| $6.43M | 2.32% | 190,000 -36,388 | -16% | -$1.23M |
|
|
TCDA
23
DELISTED
Tricida, Inc. Common Stock
TCDA
| $6.02M | 2.18% | 195,000 | – | – |
|
|
ATXI
24
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
| $5.68M | 2.05% | 952,600 +22,600 | +2% | +$135K |
|
25
FibroGen
FGEN
$47.8M
| $5.55M | 2.01% | 150,000 | – | – |
|